

04<sup>th</sup> November, 2022

To,  
The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal Street  
Mumbai - 400 001

**Scrip code: 531015**

Dear Sir/Madam,

**Sub:** Outcome of Board Meeting held on 04<sup>th</sup> November, 2022  
**Ref:** Pursuant to Reg.30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,

With reference to the subject cited above, we wish to inform you that the Board of Directors of the Company at its meeting held on Friday, the 04<sup>th</sup> November, 2022 at 4.00 P.M at registered office of the Company, inter alia,

- (i) Approved the Un Audited Standalone Financial Results of the Company for the quarter ended 30<sup>th</sup> September, 2022 & Auditors Limited Review Report thereon;

The meeting commenced at 4.00 p.m. and concluded at 4.30 p.m.

Request you to take the above information on records.

Thanking you,

Yours Faithfully,

For Venmax Drugs and Pharmaceuticals Limited

  
N. Krishnaiah  
Director  
DIN: 07279009



**VENMAX DRUGS AND PHARMACEUTICALS LIMITED**  
H.No.1-140, Rajeswari Ware House, Opposite to Sri Convention, Kompally, Quthbullapur Hyderabad Rangareddy TG 500055  
(CIN: L34230TG1988PLC009102)

**Un-Audited Financial Results for the Quarter and Six Months Ended 30th, September 2022**

S No	Particulars	Quarter Ended			Half Year ended		Year Ended
		Sep. 30th 2022	Jun. 30th 2022	Sep 30th 2021	Sep 30th, 2022	Sep 30th, 2021	March 31st, 2022
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	<b>Income</b>						
	a) Revenue from Operations	-	-	-	-	-	-
	Total Revenue from operations	-	-	-	-	-	-
	b) Other Income	5.00	5.00	-	10.00	-	198.30
	<b>Total Income</b>	<b>5.00</b>	<b>5.00</b>	<b>-</b>	<b>10.00</b>	<b>-</b>	<b>198.30</b>
2	<b>Expenses</b>						
	a) Cost of materials Consumed	-	-	-	-	-	-
	b) Changes in inventories	-	-	-	-	-	-
	c) Employee benefits expense	0.99	0.30	0.30	1.29	0.60	1.20
	d) Finance costs	-	-	-	-	-	-
	e) Depreciation and amortization expenses	0.20	0.20	0.23	0.40	0.46	0.91
	f) Other expenses	5.35	1.37	2.88	6.72	5.77	11.53
	<b>Total Expenses (a to f)</b>	<b>6.54</b>	<b>1.87</b>	<b>3.41</b>	<b>8.41</b>	<b>6.83</b>	<b>13.68</b>
3	<b>Profit before tax (1-2)</b>	<b>(1.54)</b>	<b>3.13</b>	<b>(3.41)</b>	<b>1.59</b>	<b>(6.83)</b>	<b>184.66</b>
4	<b>Tax expenses</b>						
	- Income Tax	-	-	-	-	-	-
	- Deferred Tax	(0.05)	0.16	0.01	0.11	0.02	0.03
5	<b>Net Profit for the period (3-4)</b>	<b>(1.49)</b>	<b>2.97</b>	<b>(3.42)</b>	<b>1.48</b>	<b>(6.85)</b>	<b>184.63</b>
6	<b>Other comprehensive income</b>						
	a) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
7	<b>Total Comprehensive income (5+6)</b>	<b>(1.49)</b>	<b>2.97</b>	<b>(3.42)</b>	<b>1.48</b>	<b>(6.85)</b>	<b>184.63</b>
8	<b>Paid-up Equity Share Capital</b> (Rs.10/- per Equity Share)	523.89	523.89	523.89	523.89	523.89	523.89
9	<b>Other Equity</b>						
10	<b>Earnings per share</b> (Face Value of Rs.10/- each)						
	(a) Basic (In Rs.)	(0.03)	0.06	(0.07)	0.03	(0.13)	3.52
	(b) Diluted (In Rs.)	(0.03)	0.06	(0.07)	0.03	(0.13)	3.52

1 These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 (Indian Accounting Standards) Rules 2015 as amended by the companies (Indian Accounting standards) (amendment) rules 2016.

2 The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 04-11-2022.

3 The Financial results are reviewed by the statutory auditor's as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

4 The full format of the Quarterly Financial Results are available on company's website and the stock exchange's website www.bseindia.com.

5 Previous year/period figures have been regrouped, wherever necessary, in line with the current period/year presentation.

Place: Hyderabad  
Date: 04-11-2022



By and on behalf of the Board  
For Venmax Drugs & Pharmaceuticals Limited

*N. Krishnaiah*  
Nooka Krishnaiah  
Director  
DIN: 07275009

<b>VENMAX DRUGS AND PHARMACEUTICALS LIMITED</b>		
H.No.1-140, Rajeswari Ware House, Opposite to Sri Convention, Kompally, Quthbullapur Hyderabad Rangareddi TG 500055 (CIN: L24239TG1988PLC009102)		
<b>STATEMENT OF ASSETS AND LIABILITIES</b>		
(Rs. In Lakhs)		
Particulars	As at 30.09.2022	As at 31.03.2022
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
Property, Plant and Equipment	5.28	5.56
Other Intangible Assets	2.43	2.55
Financial Assets:		
- Investments	-	-
- Other financial assets	-	-
Deferred Tax Assets (Net)	-	-
Other non-current assets	-	-
	<b>7.71</b>	<b>8.11</b>
<b>Current Assets</b>		
Inventories	-	-
Financial Assets:		
- Investments	-	-
- Trade Receivables	3.64	3.64
- Cash and cash Equivalents	0.02	0.02
- Bank balances other than cash and cash equivalents	0.01	0.01
Current Tax Assets (Net)	-	-
Other current assets	9.58	9.58
	<b>13.25</b>	<b>13.25</b>
	<b>20.96</b>	<b>21.36</b>
<b>TOTAL ASSETS</b>		
	<b>20.96</b>	<b>21.36</b>
<b>EQUITY AND LIABILITIES</b>		
Equity		
Equity Share Capital	523.89	523.89
Other Equity	(616.42)	(617.90)
Total Equity	(92.53)	(94.01)
<b>LIABILITIES</b>		
<b>Non-Current Liabilities</b>		
Financial Liabilities		
- Borrowings	-	-
Provisions	0.57	0.46
Deferred Tax Liabilities (Net)	-	-
	<b>0.57</b>	<b>0.46</b>
<b>Current Liabilities</b>		
Financial Liabilities		
- Borrowings	24.90	34.90
- Trade Payables		
(A) total outstanding dues of micro enterprises and small enterprises; and	-	-
(B) total outstanding dues of creditors other than micro enterprises and small enterprises	47.06	47.06
- Other Financial Liabilities	24.20	24.20
Current Tax Liabilities (Net)	-	-
Provisions	1.18	1.18
Other current liabilities	15.58	7.57
	<b>112.92</b>	<b>114.91</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>20.96</b>	<b>21.36</b>



**VENMAX DRUGS AND PHARMACEUTICALS LIMITED**  
**Cash Flow Statement For The period Ended 30th September 2022**

(Rs. In Lakhs)

PARTICULARS	Half Year ended Sept 30, 2022	Year ended Mar 31, 2022
	Un/Audited	Audited
<b>A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit as per Profit & Loss A/c	1.59	194.66
Adjustment for :		
Depreciation	0.40	0.91
Other comprehensive income	-	-
Net Operating Profit Before Working Capital	1.99	185.57
Changes		
Adjustment for :		
Trade & Other Receivables	-	(0.01)
Changes in inventory	-	1.00
Other Current Assets	-	0.59
Trade Payables	-	4.68
Other Financial liabilities	8.01	1.80
Other current liabilities	-	(3.11)
Provisions	10.00	190.51
Net Cash from Operating Activities	-	-
Direct taxes paid	10.00	190.51
Net Cash from Operating Activities		
<b>B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Fixed Assets	-	-
Net Cash from Investing Activities		
<b>C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
From Bank Borrowings	(10.00)	(198.00)
Proceeds from long/short term borrowings	(10.00)	(198.00)
Net Cash from Financing Activities		
Net Increase in Cash & Cash Equivalents	(0.00)	(7.49)
Add : Opening Cash & Cash Equivalents	0.03	7.53
Cash and Cash equivalents at the end of the year	0.03	0.03
<b>1) Cash and Cash equivalents includes:</b>		
	Half Year ended Sept 30, 2022	Year ended Mar 31, 2022
Cash on hand	0.02	0.02
<b>Cash Equivalents:</b>		
Current Accounts	0.01	0.01
Deposits against BG	-	-
<b>Total</b>	0.03	0.03



VENMAX DRUGS AND PHARMACEUTICALS LIMITED  
H.No.1-140, Rajeswari Ware House, Opposite to Sri Convent, Kompally, Quthbullapur Hyderabad Kaargareddi TG 500055  
(CIN: L24230TG1988PLC009102)

Extract of Un-audited financial results for the Quarter and Six Months Ended 30th September, 2022

Rs. In Lakhs

Sl.	Particulars	Quarter ended		Half Year ended		Year ended
		Sep. 30th 2022	Jun. 30th 2022	Sep 30th 2021	Sep 30th, 2021	
		Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Total Income	5.00	5.00	0.00	10.00	0.00
2	Net Profit (before Tax, Exceptional and/or Extraordinary Items)	(1.54)	3.13	(3.41)	1.59	(6.83)
3	Net Profit before tax (after Exceptional and/or Extraordinary Items)	(1.54)	3.13	(3.41)	1.59	(6.83)
4	Net Profit after tax (after Exceptional and/or Extraordinary Items)	(1.49)	2.97	(3.42)	1.48	(6.85)
5	Total Comprehensive Income [Comprising Profit after tax and Other Comprehensive Income (after tax)]	0.00	0.00	0.00	0.00	0.00
6	Paid up Equity Share Capital (Rs.10/- Per Equity Share)	523.89	523.89	523.89	523.89	523.89
7	Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year ended	-	-	-	-	(617.90)
8	Earnings Per Share (of Rs. 10/- each) (Not Annualised)	(0.03)	0.06	(0.07)	0.03	(0.13)
a) Basic		(0.03)	0.06	(0.07)	0.03	(0.13)
b) Diluted		(0.03)	0.06	(0.07)	0.03	3.52

The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 04-11-2022. Note : The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Un Audited Financial Results are available on company's website at pharmaxia.in and the stock exchange's website www.bseindia.com.

By and on behalf of the Board  
For Venmax Drugs & Pharmaceuticals Limited

*N. Srinivas*  
Nooka Krishniah  
Director

DIN: 07279009



Place : Hyderabad  
Date: 04-11-2022



**Independent Auditor's Report on Quarterly and Year to date Unaudited financial Results of M/s VENMAX DRUGS AND PHARMACEUTICALS LIMITED pursuant to Regulation 33 of the SEBI (Listing and Obligations and Disclosure requirements) Regulations, 2015.**

To the Board of Directors of,

**VENMAX DRUGS AND PHARMACEUTICALS LIMITED.**

We have reviewed the accompanying statement of unaudited financial results of **VENMAX DRUGS AND PHARMACEUTICALS LIMITED** ('The Company') for the quarter ended September 30, 2022 and for the period from 1<sup>st</sup> April, 2022 to 30<sup>th</sup> September, 2022. This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements..

**For NSVR & Associates LLP,**  
Chartered Accountants,  
FRN: 008801S/S200060

  
**Suresh Gannamani,**

Partner,

Membership No: 226870,

UDIN: 22226870BBZXJY2202.



Place: Hyderabad

Date: 04/11/2022.